In BxPC3 cells, single treatment with PHT-427 produced a Caspase-3 activity effect that was not significantly higher than zero. In a competition assay using CGA-modified MM-captured AKT protein, AKT bands in the SC79 and PHT-427 groups were clearly detected by Western blot compared with the DTT group. Following treatment with serial dilutions of PHT-427, no significant difference was seen in normalised MCF10A-WT and CDH1−/− cell counts. In AsPC1 cells, PHT-427, MK-2206, or their combination showed no significant effect on Caspase-3 activity. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Caspase activity in BxPC3 cells
Cell-based study · BxPC3 cells [1]
In BxPC3 cells, single treatment with PHT-427 produced no statistically significant effect on Caspase-3 activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- 16 h at 37 °C in a 5% CO2 atmosphere
- Method
- cells + Caspase-3 substrate + compound X + media
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: PHT-427
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Combinatorial drug-response screening (S30); Results > Cell line-specific drug combinations and validation (S60); Methods > Microfluidic setup (S111); Methods > Preparation of cells for microfluidic experiments (S140, S142); Methods > Preparation of drugs and Caspase-3 substrate (S147, S148, S152); Methods > Data processing (S165); Fig. 3 legend (S200)
Caspase-3 activity: Caspase-3 activity; comparator: cells + Caspase-3 substrate + media + media — Results > Cell line-specific drug combinations and validation (S60); Fig. 3 legend (S200)
AKT detection following probe competition
Cell-based study · CGA-modified MM-captured AKT protein [2]
PHT-427 was added to compete with the CGA-modified MM probe in captured AKT protein. Compared with the DTT group, AKT bands were clearly detected by Western blot in the SC79 and PHT-427 groups.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 μM
- Method
- added to compete with the CGA-modified MM probe
- Reported limits
- Not stated in the sentences used: schedule, vehicle.
Methods and source locations
Compound reported in the paper: PHT-427
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.8. Competitive Test against AKT Using CGA-Modified MMs (S58, S60, S64, S65, S66); 3. Results > 3.3. CGA Binds to the PH Domain of AKT (S116)
AKT concentration was determined using SDS-PAGE and Western blot: AKT concentration was determined using SDS-PAGE and Western blot; comparator: captured AKT proteins were released with 250 μL of DTT (100 μM) — 2. Materials and Methods > 2.8. Competitive Test against AKT Using CGA-Modified MMs (S66); 3. Results > 3.3. CGA Binds to the PH Domain of AKT (S116)
Normalised cell counts following treatment
Cell-based study · MCF10A-WT and CDH1−/− [3]
Normalised MCF10A-WT and CDH1−/− cell counts 48 h after treatment with serial dilutions of PHT-427: No significant difference was seen.
Literature-Reported Treatment Conditions
- Exposure duration
- 48 h
- Method
- treatment with serial dilutions
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: PHT-427
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.1. Allosteric AKT Inhibitors Preferentially Target Breast Cells Lacking CDH1 (S9); 4. Materials and Methods > 4.3. Nuclei Enumeration Assay (S99); Figure 1 legend (S153, S156)
Normalised MCF10A-WT and CDH1−/− cell counts: Normalised MCF10A-WT and CDH1−/− cell counts; comparator: MCF10A-WT and CDH1−/−; normalised to the vehicle control for each cell line. — 2. Results > 2.1. Allosteric AKT Inhibitors Preferentially Target Breast Cells Lacking CDH1 (S9); Figure 1 legend (S153)
Caspase activity in AsPC1 cells
Cell-based study · AsPC1 cells [1]
In AsPC1 cells, treatment with PHT-427, MK-2206, or their combination showed no significant effect on Caspase-3 activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- 16 h at 37 °C in a 5% CO2 atmosphere
- Method
- cells + Caspase-3 substrate + compound X + media
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: PHT-427
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Combinatorial drug-response screening (S30); Results > Cell line-specific drug combinations and validation (S61); Methods > Microfluidic setup (S111); Methods > Preparation of cells for microfluidic experiments (S140, S142); Methods > Preparation of drugs and Caspase-3 substrate (S147, S148, S152); Methods > Data processing (S165); Fig. 3 legend (S200, S203, S204); Fig. 4 legend (S206)
Caspase-3 activity: Caspase-3 activity; comparator: control condition (cells + Caspase-3 substrate + media + media); one-tailed t-test: z-score equal to 0 (i.e., median activation across all conditions). — Results > Cell line-specific drug combinations and validation (S61); Fig. 3 legend (S200, S204)